Search

Your search keyword '"Blais L"' showing total 397 results
Start Over Author "Blais L"
397 results on '"Blais L"'

1. Adjusting Historical Costs for Inflation with the Use of Standardized Automated Tools

Author

Guertin JR, Chouinard NH, Forget A, and Blais L

Subjects
n/a, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Jason Robert Guertin,1– 3 Naomi Hope Chouinard,1– 3 Amélie Forget,4,5 Lucie Blais4,5 1Centre de recherche du CHU de Québec-Université Laval, Quebec City, Canada; 2Department of Social and Preventive Medicine, Faculty of Medicine, Université Laval, Quebec City, Canada; 3Centre de recherche en organogénèse expérimentale de l’Université Laval/LOEX, Quebec City, Canada; 4Faculty of Pharmacy, Université de Montréal, Montréal, Canada; 5Centre de recherche du Centre intégré universitaire de santé et de services sociaux du Nord-de-l’Île-de-Montréal, Montréal, CanadaCorrespondence: Jason Robert Guertin, Centre de recherche du CHU de Québec – Université Laval, Hôpital du Saint-Sacrement, 1050 Chemin Sainte-Foy, Local J1-11, Quebec City, G1S 4L8, Canada, Tel +1 418-682-7511 ext 82516, Email jason.guertin@fmed.ulaval.ca

Published
2024

2. Polypharmacy and Excessive Polypharmacy Among Persons Living with Chronic Pain: A Cross-Sectional Study on the Prevalence and Associated Factors

Author

Zahlan G, De Clifford-Faugère G, Nguena Nguefack HL, Guénette L, Pagé MG, Blais L, and Lacasse A

Subjects
chronic pain, polypharmacy, excessive polypharmacy, prevalence, associated factors, determinants., Medicine (General), R5-920
Abstract

Ghita Zahlan,1 Gwenaelle De Clifford-Faugère,1 Hermine Lore Nguena Nguefack,1 Line Guénette,2,3 M Gabrielle Pagé,4,5 Lucie Blais,6 Anaïs Lacasse1 1Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue, Rouyn-Noranda, Quebec, Canada; 2Faculté de pharmacie, Université Laval, Quebec, Quebec, Canada; 3Centre de recherche, CHU de Québec - Université Laval, Quebec, Quebec, Canada; 4Centre de recherche, Centre hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada; 5Département d’anesthésiologie et de médecine de la douleur, Faculté de médecine, Université de Montréal, Montreal, Quebec, Canada; 6Faculté de pharmacie, Université de Montréal, Montreal, Quebec, CanadaCorrespondence: Anaïs Lacasse, Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue, 445, boul. de l’Université, Rouyn-Noranda, Qc, J9X 5E4, Canada, Tel +1 819 762-0971, 2722, Email lacassea@uqat.caPurpose: Polypharmacy can be defined as the concomitant use of ≥ 5 medications and excessive polypharmacy, as the use of ≥ 10 medications. Objectives were to (1) assess the prevalence of polypharmacy and excessive polypharmacy among persons living with chronic pain, and (2) identify sociodemographic and clinical factors associated with excessive polypharmacy.Patients and Methods: This cross-sectional study used data from 1342 persons from the ChrOnic Pain trEatment (COPE) Cohort (Quebec, Canada). The self-reported number of medications currently used by participants (regardless of whether they were prescribed or taken over-the-counter, or were used for treating pain or other health issues) was categorized to assess polypharmacy and excessive polypharmacy.Results: Participants reported using an average of 6 medications (median: 5). The prevalence of polypharmacy was 71.4% (95% CI: 69.0– 73.8) and excessive polypharmacy was 25.9% (95% CI: 23.6– 28.3). No significant differences were found across gender identity groups. Multivariable logistic regression revealed that factors associated with greater chances of reporting excessive polypharmacy (vs < 10 medications) included being born in Canada, using prescribed pain medications, and reporting greater pain intensity (0– 10) or pain relief from currently used pain treatments (0– 100%). Factors associated with lower chances of excessive polypharmacy were using physical and psychological pain treatments, reporting better general health/physical functioning, considering pain to be terrible/feeling like it will never get better, and being employed.Conclusion: Polypharmacy is the rule rather than the exception among persons living with chronic pain. Close monitoring and evaluation of the different medications used are important for all persons, especially those with limited access to care.Keywords: chronic pain, polypharmacy, excessive polypharmacy, prevalence, associated factors, determinants

Published
2023

3. Difference in drug cost between private and public drug plans in Quebec, Canada

Author

Chamoun M., Forget A., Chabot I., Schnitzer M., and Blais L.

Subjects
Drug insurance, Drug plan, Drug cost difference, Public aspects of medicine, RA1-1270
Abstract

Abstract Background We expect a difference in drug cost between private drug plans and the Public Drug Plan (PDP) because the dispensing fee is fixed and regulated by the PDP for publicly insured patients, whereas it is determined freely by the pharmacy owner for privately insured patients. This study compared the drug cost of Quebec residents covered by private drug plans with those covered by PDP. Methods We used a sample of prescriptions filled between 1 January 2015 and 23 May 2019 selected from reMed, a database of Quebecers’ drug claims. We created strata of prescriptions filled by privately insured patients and matched them with strata of prescriptions filled by publicly insured patients based on the Drug Identification Number, quantity dispensed, number of days of supply, pharmacy identifier, and a date corresponding to the publication of List of Medications of Régie de l’Assurance Maladie du Québec. The differences in drug cost between private plans and the PDP were analyzed with linear regression models using prescription strata as the unit of analysis. Results Based on 38 896 prescription strata, we observed that privately insured patients payed $9·35 (95% confidence interval [CI]: 5·58; 13·01) more on average per drug prescription than publicly insured patients, representing a difference of 17·6%. Conclusions This study showed that, on average, drug cost is substantially higher for privately insured Quebecers. Knowing that adherence to treatment is affected by drug cost, these results will help public health authorities to make informed decisions about drug policies.

Published
2022
Full Text
View/download PDF

4. Guided asthma self-management or patient self-adjustment? Using patients’ narratives to better understand adherence to asthma treatment

Author

Farnesi BC, Ducharme FM, Blais L, Collin J, Lavoie KL, Bacon SL, McKinney ML, and Peláez S

Subjects
asthma, adherence, self-management, written action plan, patient-physician relationship, narrative inquiry, Medicine (General), R5-920
Abstract

Biagina-Carla Farnesi,1 Francine M Ducharme,2,3 Lucie Blais,4 Johanne Collin,4 Kim L Lavoie,5,6 Simon L Bacon,1,6 Martha L McKinney,7 Sandra Peláez3,8 1Department of Health, Kinesiology, and Applied Physiology, Concordia University, Montreal, QC Canada; 2Departments of Pediatrics and of Social and Preventive Sciences, University of Montreal, Montreal, QC Canada; 3Research Centre, CHU Sainte-Justine, University of Montreal, Montreal, QC Canada; 4Faculty of Pharmacy, University of Montreal, Montreal, QC Canada; 5Psychology Department, University of Quebec at Montreal, Montreal, QC Canada; 6Research Center, Sacré-Cœur de Montréal Hospital, CIUSSS du Nord-de-l’Ile-de-Montréal, Montreal, QC Canada; 7CHU Ste-Justine, University of Montreal, Montreal, QC Canada; 8School of Kinesiology and Physical Activity Sciences, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada Purpose: The purpose of this study was to better understand patients’ perspective of asthma self-management by focusing on the sociocultural and medical context shaping patients’ illness representations and individual decisions. Patients and methods: We conducted a secondary analysis of semi-structured interviews carried out as part of a multicentered collective qualitative case study. In total, 24 patients, aged 2–76 years with a confirmed diagnosis of asthma (or were parents of a child), who renewed the prescription for inhaled corticosteroids in the past year, participated in this study. The thematic analysis focused on asthma-related events and experiences reported by the patients. Consistent with narrative inquiry, similar patterns were grouped together, and three vignettes representing the different realities experienced by the patients were created. Results: The comparison of experiences and events reported by the patients suggested that patients’ perceptions and beliefs regarding asthma and treatment goals influenced their self-management-related behaviors. More specifically, the medical context in which the patients were followed (ie, frame in which the medical encounter takes place, medical recommendations provided) contributed to shape their understanding of the disease and the associated treatment goals. In turn, a patient’s perception of the disease and the treatment goals influenced asthma self-management behaviors related to environmental control, lifestyle habits, and medication intake. Conclusion: Current medical recommendations regarding asthma self-management highlight the importance of the physicians’ guidance through the provision of a detailed written action plan and asthma education. These data suggest that while physicians contribute to shaping patients’ beliefs and perceptions about the disease and treatment goals, patients tend to listen to their own experience and manage the disease accordingly. Thus, a medical encounter between the patient and the physician, aiming at enhancing a meaningful conversation about the disease, may lead the patient to approach the disease in a more effective manner, which goes beyond taking preventative paths to avoid symptoms. Keywords: asthma, adherence, self-management, written action plan, patient-physician relationship, narrative inquiry

Published
2019

5. Efficacy of brief motivational interviewing to improve adherence to inhaled corticosteroids among adult asthmatics: results from a randomized controlled pilot feasibility trial

Author

Lavoie KL, Moullec G, Lemiere C, Blais L, Labrecque M, Beauchesne MF, Pepin V, Cartier A, and Bacon SL

Subjects
Medicine (General), R5-920
Abstract

Kim L Lavoie,1–3 Gregory Moullec,1,2,4 Catherine Lemiere,2 Lucie Blais,2 Manon Labrecque,2 Marie-France Beauchesne,2 Veronique Pepin,2,4 André Cartier,2 Simon L Bacon1,2,41Montreal Behavioural Medicine Centre, 2Research Centre, Hôpital du Sacré-Cœur de Montréal – A University of Montreal Affiliated Hospital, Montréal, 3Department of Psychology, University of Quebec at Montreal (UQAM), Succursale Center-Ville, Montreal, 4Department of Exercise Science, Concordia University, Montreal, Quebec, CanadaPurpose: Daily adherence to inhaled corticosteroid (ICS) regimens is one of the most important factors linked to achieving optimal asthma control. Motivational interviewing (MI) is a client-centered communication style that focuses on enhancing intrinsic motivation to engage in appropriate self-management behaviors. MI has been shown to improve a variety of health behaviors including medication adherence in other disorders, but its efficacy for the improvement of ICS adherence in asthmatics has yet to be examined. This pilot “proof of concept” trial assessed the feasibility of MI to improve daily ICS adherence and asthma control levels in adult asthmatics.Methods: Fifty-four poorly controlled (Asthma Control Questionnaire [ACQ] score ≥1.5), highly nonadherent (filled

Published
2014

7. Experimental investigation on stainless steel welding with a 15 kW fibre laser

Author

Foster, M., Beaulieu, R., Blais, L., Caron, G., and Langlois, M.

Subjects
Infrared radiation -- Usage, Steel, Stainless -- Properties, Welding -- Methods, Laser beams -- Usage, Physics
Abstract

In the present study, attenuation of the laser beam because of the induced plume during bead-on-plate welding of an austenitic stainless steel plate with a 15 kW fibre laser beam, was investigated to better understand laser welding phenomena. A high-speed video camera was used to monitor the plume and keyhole behaviour. Attenuation and refraction levels, due to the induced plume, were measured by different wavelengths laser probes. Finally, a high resolution spectrometer was used to analyze spectral emission from the induced plasma plume by the fibre laser beam. The Boltzmann plot method was used to estimate the temperature of laser-induced plasma plume and Saha's equation was applied to calculate the ionization degree. PACS No.: 42.62.Cf. Afin de mieux comprendre le mecanisme du soudage par laser, nous etudions ici l'attenuation d'un faisceau laser due au panache forme lors d'une soudure sur une plaque d'acier inoxydable austenitique a l'aide d'un laser a fibre de 15 kW. Une camera haute vitesse a enregistre le comportement du panache et du capillaire de vaporisation (keyhole). Nous avons mesure l'attenuation et la refraction engendrees par le panache a l'aide de sondes laser de differentes longueurs d'onde. Finalement, un spectrometre a haute resolution nous permet d'analyser le spectre d'emission du panache de plasma genere par le faisceau du laser a fibre. Nous utilisons la methode de Boltzmann pour determiner la temperature du plasma et l'equation de Saha pour estimer le degre d'ionisation. [Traduit par la Redaction], 1. Introduction When an infrared laser beam hits a solid metal target, the major part of the laser beam radiation is reflected at the target surface while the rest is [...]

Published
2014
Full Text
View/download PDF

8. Difference in drug cost between private and public drug plans in Quebec, Canada

Author

Chamoun M., Forget A., Chabot I., Schnitzer M., and Blais L.

Subjects
Pharmaceutical Preparations, Health Policy, Quebec, Humans, Insurance, Pharmaceutical Services, Drug Prescriptions, Drug Costs
Abstract

Background We expect a difference in drug cost between private drug plans and the Public Drug Plan (PDP) because the dispensing fee is fixed and regulated by the PDP for publicly insured patients, whereas it is determined freely by the pharmacy owner for privately insured patients. This study compared the drug cost of Quebec residents covered by private drug plans with those covered by PDP. Methods We used a sample of prescriptions filled between 1 January 2015 and 23 May 2019 selected from reMed, a database of Quebecers’ drug claims. We created strata of prescriptions filled by privately insured patients and matched them with strata of prescriptions filled by publicly insured patients based on the Drug Identification Number, quantity dispensed, number of days of supply, pharmacy identifier, and a date corresponding to the publication of List of Medications of Régie de l’Assurance Maladie du Québec. The differences in drug cost between private plans and the PDP were analyzed with linear regression models using prescription strata as the unit of analysis. Results Based on 38 896 prescription strata, we observed that privately insured patients payed $9·35 (95% confidence interval [CI]: 5·58; 13·01) more on average per drug prescription than publicly insured patients, representing a difference of 17·6%. Conclusions This study showed that, on average, drug cost is substantially higher for privately insured Quebecers. Knowing that adherence to treatment is affected by drug cost, these results will help public health authorities to make informed decisions about drug policies.

Published
2021

9. Feasibility of Implementing a Web-based Tool Built from Pharmacy Claims Data (e-MEDRESP) to Monitor Adherence to Respiratory Medications in Primary Care

Author

Lemière C, Beauchesne M, Forget A, Blais L, and Yousif A

Subjects
business.industry, Claims data, medicine, Web application, Pharmacy, Medical emergency, Primary care, business, medicine.disease, Respiratory medications
Abstract

Objectives: e-MEDRESP is a novel web-based tool that provides easily interpretable information on patient adherence to asthma/chronic obstructive pulmonary disease medications, using pharmacy claims data. This study investigated the feasibility of implementing e-MEDRESP in primary care. Materials and Methods: In this 16-month prospective cohort study, e-MEDRESP was integrated into electronic medical records. Nineteen family physicians and 346 of their patients were enrolled. Counters embedded in the tool tracked physician use during the follow-up. Patient/physician satisfaction with e-MEDRESP was evaluated though telephone interviews and online questionnaires. The capacity of e-MEDRESP to improve adherence was explored using a pre–post analysis. Results: Overall, 252 patients had at least one medical visit during follow-up. e-MEDRESP was consulted by 15 (79%) physicians for 85 (34%) patients during clinic visits. Seventy-three patients participated in telephone interviews; 84% reported discussing their medication use with their physician; 33% viewed their e-MEDRESP report and indicated that it was easy to interpret. The physicians reported that the tool facilitated their evaluation of their patients’ medication adherence (mean ± standard deviation rating: 4.8 ± 0.7, on a 5-point Likert scale). Although the pre–post analysis did not reveal improved adherence in the overall cohort, adherence improved significantly in patients whose adherence level was

Published
2021

23. Treatment of Clostridium difficile infection in a French university hospital

Author

Khanafer, N., Blais, L., Barbut, F., Hirschel, B., Vanhems, Philippe, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio]
Published
2015

24. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease

Author

Renoux, C, Dell'Aniello, S, Khairy, P, Marras, C, Bugden, S, Turin, TC, Blais, L, Tamim, H, Evans, C, Steele, R, Dormuth, C, Ernst, P, Renoux, C, Dell'Aniello, S, Khairy, P, Marras, C, Bugden, S, Turin, TC, Blais, L, Tamim, H, Evans, C, Steele, R, Dormuth, C, and Ernst, P

Abstract

AIM: Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson's disease (PD). Concerns have been raised regarding an increased risk of ventricular tachyarrhythmia and sudden cardiac death (VT/SCD) associated with domperidone in the general population. However, the risk in PD is unknown. METHODS: We conducted a multicentre retrospective cohort study using administrative databases from seven Canadian provinces and the UK Clinical Practice Research Datalink. Using a nested case-control analysis, we estimated the rate ratios (RRs) of VT/SCD associated with domperidone use compared to no use in patients newly-diagnosed with PD. VT/SCD events were identified using administrative medical records and vital statistics with a manual review of all potential cases. Meta-analytic methods were used to estimate overall effects across sites. RESULTS: Among 214 962 patients with PD, 2907 cases of VT/SCD were identified during 886 581 person-years of follow-up (incidence rate 3.28 per 1000 persons per year). Current use of domperidone was associated with a non-statistically significant 22% increased risk of VT/SCD (RR 1.22; 95% CI 0.99-1.50) compared with no use. The risk was significantly elevated in those with a history of cardiovascular disease (RR 1.38; 95% CI 1.07-1.78), but not in those without (RR 1.21; 95% CI 0.81-1.81). Dose and duration of use did not affect the magnitude of the risk. CONCLUSION: Domperidone use may increase the risk of VT/SCD in patients with PD, particularly those with a history of cardiovascular disease. This risk may be underestimated because of imprecision in identifying VT/SCD events.

Published
2016

25. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study

Author

Vanasse, A., primary, Blais, L., additional, Courteau, J., additional, Cohen, A. A., additional, Roberge, P., additional, Larouche, A., additional, Grignon, S., additional, Fleury, M.-J., additional, Lesage, A., additional, Demers, M.-F., additional, Roy, M.-A., additional, Carrier, J.-D., additional, and Delorme, A., additional

Published
2016
Full Text
View/download PDF

26. The Canadian Society for Epidemiology and Biostatistics 2016 National Student Conference001INVESTIGATING ECOLOGICAL DETERMINANTS OF MALARIA VECTOR DISTRIBUTION IN RURAL TANZANIA “A MULTI-SCALAR INVESTIGATION”002PREVALENCE AND RISK FACTORS OF TUBERCULOSIS INFECTION AMONG HEALTHCARE TRAINEES IN SOUTH INDIA003SPATIAL MODELLING OF LUNG AND THYROID CANCERS IN UNITED STATES COUNTIES004A MEDIATION ANALYSIS TO ASSESS THE IMPACT OF INHALED CORTICOSTEROIDS (ICSS) DURING PREGNANCY ON BIRTHWEIGHT005MODELLING HUMAN RISK OF WEST NILE VIRUS IN ONTARIO, 2002-2013: INCORPORATING SURVEILLANCE AND ENVIRONMENTAL DATA006EXPLORING THE HEALTH OUTCOMES OF VARIOUS PAN-CANADIAN CERVICAL CANCER SCREENING PROGRAMS USING MICROSIMULATION MODELING007INTEGRATIVE ANALYSIS OF MICRORNA AND GENE EXPRESSION DATA USING SPARSE CANONICAL CORRELATION ANALYSIS008CONDITIONAL DEPENDENCE MODELS UNDER COVARIATE MEASUREMENT ERROR009ASSOCIATION BETWEEN FOOD INSECURITY AND HIV VIRAL SUPPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS010ANTIBIOTICS VERSUS APPENDECTOMY FOR UNCOMPLICATED APPENDICITIS: A GLOBAL HEALTH PERSPECTIVE

Author

Homenauth, E, primary, Ghiasi, M, primary, Feldman, L, primary, Arrouf, N, primary, Mallya, S, primary, Lacombe, J, primary, Pichika, SC, primary, Zhao, K, primary, Aibibula, W, primary, Krishnan, R, primary, Kajeguka, D, additional, Kaaya, R, additional, Protopopoff, N, additional, Mosha, F, additional, Desrochers, R, additional, Watts, A, additional, Kulkarni, M, additional, Saravu, K, additional, Nair, S, additional, Mukhopadhyay, C, additional, George, LS, additional, Pai, M, additional, Jiang, H, additional, Brown, P, additional, Blais, L, additional, Lefebvre, G, additional, Samoilenko, M, additional, Jolly, A, additional, Roy-Gagnon, MH, additional, Sander, B, additional, Gauvreau, CL, additional, Memon, S, additional, Popadiuk, C, additional, Flanagan, WM, additional, Nadeau, C, additional, Coldman, AJ, additional, Wolfson, MC, additional, Miller, AB, additional, Acar, E, additional, Cox, J, additional, Hamelin, A-M, additional, McLinden, T, additional, Klein, MB, additional, Brassard, P, additional, Chong, M, additional, and Martin, J, additional

Published
2016
Full Text
View/download PDF

32. French guidelines for the management of challenging behavioral disorders following traumatic brain injury: Symptoms and assessment

Author

Stéfan, A., primary, Luauté, J., additional, Plantier, D., additional, Wiart, L., additional, Hamonet, J., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.M., additional, Blais, L., additional, Cazals, M.C., additional, Destaillats, J.M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2014
Full Text
View/download PDF

33. Prise en charge des troubles du comportement chez les traumatisés crâniens, recommandations française de bonne pratique : traitements médicamenteux

Author

Plantier, D., primary, Luauté, J., additional, Wiart, L., additional, Stefan, A., additional, Hamonet, J., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.M., additional, Blais, L., additional, Cazals, M.C., additional, Destaillats, J.M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2014
Full Text
View/download PDF

35. Prise en charge des troubles du comportement chez les traumatisés crâniens, recommandations françaises de bonne pratique : quels symptômes et quelles évaluations ?

Author

Stéfan, A., primary, Luauté, J., additional, Plantier, D., additional, Wiart, L., additional, Hamonet, J., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.M., additional, Blais, L., additional, Cazals, M.C., additional, Destaillats, J.M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2014
Full Text
View/download PDF

36. French guideline for the management of behavioral disorders in traumatic brain injury: Medications

Author

Plantier, D., primary, Luauté, J., additional, Wiart, L., additional, Stefan, A., additional, Hamonet, J., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.M., additional, Blais, L., additional, Cazals, M.C., additional, Destaillats, J.M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2014
Full Text
View/download PDF

37. Support disorders after traumatic brain injury, guidelines: Medications

Author

Plantier, D., primary, Luaute, J., additional, Wiart, L., additional, Stefan, A., additional, Hamonet, J., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.-M., additional, Blais, L., additional, Cazals, M.-C., additional, Destaillats, J.-M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.-M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J.-A., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2013
Full Text
View/download PDF

38. Prise en charge des troubles du comportement après traumatisme crânien, recommandations de bonne pratique : traitements médicamenteux

Author

Plantier, D., primary, Luaute, J., additional, Wiart, L., additional, Stefan, A., additional, Hamonet, J., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.-M., additional, Blais, L., additional, Cazals, M.-C., additional, Destaillats, J.-M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.-M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J.-A., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2013
Full Text
View/download PDF

39. Troubles du comportement après traumatisme crânien : quels symptômes et quelles évaluations ?

Author

Stefan, A., primary, Luaute, J., additional, Hamonet, J., additional, Wiart, L., additional, Plantier, D., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.-M., additional, Cazals, M.-C., additional, Destaillats, J.-M., additional, Durand, E., additional, Blais, L., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Montrobert, N., additional, Lucas, J.-M., additional, Malauzat, D., additional, Preziosi, J., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2013
Full Text
View/download PDF

40. Non-pharmacological treatment for behavioural troubles in brain injury patients. Review of literature

Author

Wiart, L., primary, Luauté, J., additional, Lermuzeaux, C., additional, Tell, L., additional, Stefan, A., additional, Richard, I., additional, Prouteau, A., additional, Preziosi, J., additional, Malauzat, D., additional, Montrobert, N., additional, Jagot, L., additional, Hamonet, J., additional, Fieyre, C., additional, Lucas, J.-M., additional, Destaillats, J.-M., additional, Cazals, M.-C., additional, Arnould, A., additional, Beis, J.-M., additional, Aubert, S., additional, Durand, E., additional, Fayol, P., additional, Plantier, D., additional, and Blais, L., additional

Published
2013
Full Text
View/download PDF

41. How to prevent and follow-up behavioural troubles of brain injuried patients?

Author

Hamonet-Torny, J., primary, Luauté, J., additional, Stephan, A., additional, Plantier, D., additional, Wiart, L., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.-M., additional, Blais, L., additional, Cazals, M.-C., additional, Destaillats, J.-M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.-M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J.-A., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2013
Full Text
View/download PDF

42. Troubles du comportement après traumatisme crânien : quelles stratégies thérapeutiques ?

Author

Luauté, J., primary, Hamonet, J., additional, Plantier, D., additional, Stéfan, A., additional, Wiart, L., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.-M., additional, Blais, L., additional, Cazals, M.-C., additional, Destaillats, J.-M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.-M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2013
Full Text
View/download PDF

43. Challenging behaviour following traumatic brain injury: Symptoms and assessments

Author

Stefan, A., primary, Luaute, J., additional, Hamonet, J., additional, Wiart, L., additional, Plantier, D., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.-M., additional, Cazals, M.-C., additional, Destaillats, J.-M., additional, Durand, E., additional, Blais, L., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Montrobert, N., additional, Lucas, J.-M., additional, Malauzat, D., additional, Preziosi, J., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2013
Full Text
View/download PDF

44. Techniques de soins et interventions non médicamenteuses pour la prise en charge des troubles du comportement de la personne victime d’un traumatisme crânien grave. Revue de la littérature

Author

Wiart, L., primary, Luauté, J., additional, Lermuzeaux, C., additional, Tell, L., additional, Stefan, A., additional, Richard, I., additional, Prouteau, A., additional, Preziosi, J., additional, Malauzat, D., additional, Montrobert, N., additional, Jagot, L., additional, Hamonet, J., additional, Fieyre, C., additional, Lucas, J.-M., additional, Destaillats, J.-M., additional, Cazals, M.-C., additional, Arnould, A., additional, Beis, J.-M., additional, Aubert, S., additional, Durand, E., additional, Fayol, P., additional, Plantier, D., additional, and Blais, L., additional

Published
2013
Full Text
View/download PDF

45. Behavioural disorders after traumatic brain injury: Which therapeutic strategies?

Author

Luauté, J., primary, Hamonet, J., additional, Plantier, D., additional, Stéfan, A., additional, Wiart, L., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.-M., additional, Blais, L., additional, Cazals, M.-C., additional, Destaillats, J.-M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.-M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2013
Full Text
View/download PDF

46. Comment prévenir et suivre les troubles du comportement des patients traumatisés crâniens ?

Author

Hamonet-Torny, J., primary, Luauté, J., additional, Stephan, A., additional, Plantier, D., additional, Wiart, L., additional, Arnould, A., additional, Aubert, S., additional, Beis, J.-M., additional, Blais, L., additional, Cazals, M.-C., additional, Destaillats, J.-M., additional, Durand, E., additional, Fayol, P., additional, Fieyre, C., additional, Jagot, L., additional, Lermuzeaux, C., additional, Lucas, J.-M., additional, Malauzat, D., additional, Montrobert, N., additional, Preziosi, J.-A., additional, Prouteau, A., additional, Richard, I., additional, and Tell, L., additional

Published
2013
Full Text
View/download PDF

48. QUALITY AND SAFETY OF ART THERAPIES

Author

Caballero, P., primary, Alonso, J., additional, Cortes, S., additional, Caballero Campo, M., additional, Gago, M., additional, Nunez-Calonge, R., additional, Ricciarelli, E., additional, Gomez Palomares, J. L., additional, Bruna Catalan, I., additional, Hernandez, E. R., additional, Grzegorczyk-Martin, V., additional, Belaisch-Allart, J., additional, Mayenga, J. M., additional, Kulski, O., additional, Plachot, M., additional, Darby, H. C., additional, Florensa Bargallo, M., additional, Perals Vazquez, N., additional, Esbert Algam, M., additional, Belles Fernandez, M., additional, Ballesteros Boluda, A., additional, Calderon de Oya, G., additional, Alegre de Miquel, M., additional, Choudhary, M., additional, Ramineni, A., additional, Stewart, J., additional, Cabello, Y., additional, Fernandez-Shaw, S., additional, Mercader, A., additional, Herrer, R., additional, Arroyo, G., additional, Del Rio, F., additional, Carrera, M., additional, Fernandez Sanchez, M., additional, Sumimoto, T., additional, Kataoka, N., additional, Ogata, H., additional, Mizuta, S., additional, Tokura, Y., additional, Yamada, S., additional, Ogata, S., additional, Mizusawa, Y., additional, Matsumoto, Y., additional, Okamoto, E., additional, Kokeguchi, S., additional, Shiotani, M., additional, Nagai, Y., additional, Otsuki, J., additional, Maeda, K., additional, Momma, Y., additional, Takahashi, K., additional, Chuko, M., additional, Miwa, A., additional, Nagai, A., additional, Seggers, J., additional, Haadsma, M. L., additional, La Bastide-van Gemert, S., additional, Heineman, M. J., additional, Kok, J. H., additional, Middelburg, K. J., additional, Roseboom, T. J., additional, Schendelaar, P., additional, Van den Heuvel, E. R., additional, Hadders-Algra, M., additional, Jongbloed-Pereboom, M., additional, La Bastide-Van Gemert, S., additional, Heineman, K. R., additional, Bos, A. F., additional, Kondapalli, L. A., additional, Shaunik, A., additional, Molinaro, T. A., additional, Ratcliffe, S. J., additional, Barnhart, K. T., additional, Haadsma, M., additional, Keating, P., additional, Van Hoften, J. C., additional, Veenstra-Knol, H. E., additional, Cobben, J. M., additional, Pirkevi, C., additional, Atayurt, Z., additional, Yelke, H., additional, Kahraman, S., additional, Desmyttere, S., additional, Verpoest, W., additional, Haentjens, P., additional, Verheyen, G., additional, Liebaers, I., additional, Bonduelle, M., additional, Winter, C., additional, Van Acker, F., additional, De Schrijver, F., additional, Nekkebroeck, J., additional, Pariente-Khayat, A., additional, de Laubier, A., additional, Fehily, D., additional, Lemardeley, G., additional, Merlet, F., additional, Creusvaux, H., additional, Nakajo, Y., additional, Sakamoto, E., additional, Doshida, M., additional, Toya, M., additional, Nasu, I., additional, Kyono, K., additional, Schats, R., additional, Vergouw, C. G., additional, Kostelijk, E. H., additional, Doejaaren, E., additional, Hompes, P. G. A., additional, Lambalk, C. B., additional, Nakamura, Y., additional, Takisawa, T., additional, Shibuya, Y., additional, Sato, Y., additional, Sato, K., additional, Berard, A., additional, Chaabane, S., additional, Sheehy, O., additional, Blais, L., additional, Fraser, W., additional, Bissonnette, F., additional, Monnier, P., additional, Tan, S. L., additional, Trasler, J., additional, Subramaniam, A., additional, Chiappetta, R., additional, Mania, A., additional, Trew, G., additional, Lavery, S. A., additional, van den Akker, O., additional, Purewal, S., additional, Bunnell, C., additional, Lashen, H., additional, Terriou, P., additional, Giorgetti, C., additional, Porcu-Buisson, G., additional, Roger, V., additional, Chinchole, J. M., additional, Hamon, V., additional, Allemand-Sourieu, J., additional, Cravello, L., additional, Moreau, J., additional, Chabert-Orsini, V., additional, Belva, F., additional, Roelants, M., additional, De Schepper, J., additional, Devroey, P., additional, Painter, R. C., additional, Machin, L., additional, Fearon, K., additional, Morishima, K., additional, Fujimoto, A., additional, Oishi, H., additional, Hirata, T., additional, Harada, M., additional, Hasegawa, A., additional, Osuga, Y., additional, Yano, T., additional, Kozuma, S., additional, and Taketani, Y., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results